5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Rewiring the Streptomyces cell factory for cost-effective production of biomolecules (STREPSYNTH)
Date du début: 1 déc. 2013, Date de fin: 30 nov. 2018,
STREPSYNTH aims to set-up a Streptomyces-based new industrial production platform (SNIP) for high value added biomolecules. Streptomyces lividans was chosen as a bacterial host cell because it has been already shown to be highly efficient for the extracellular production of a number of heterologous molecules that vary chemically, has a robust tradition of industrial fermentation and is fully acces ...
Voir le projet
17
Participants partenaires
TERMINÉ
Developing and Testing a novel, low-cost, effective HOOKworm VACcine to Control Human Hookworm Infection in endemic countries (HOOKVAC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
Approximately 600-700 million people are infected by hookworm, primarily in sub-Saharan Africa, Southeast Asia, and Latin America. Hookworm infection ranks number one in terms of Years Lost from Disability from a neglected infectious disease, and among the top 3 in terms of lost Disability-Adjusted Life Years. HOOKVAC will be developing the first and only vaccine for human hookworm infection. A ...
Voir le projet
9
Participants partenaires
TERMINÉ
InFLUenza virus UNIVersal VACcine development program (FLUNIVAC)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,
Effectively protecting the general population from seasonal and pandemic influenza has proven to be a challenge, since influenza viruses continue to escape from and evade immunity. Current influenza vaccines fail to provide long-lasting and broad protection against multiple strains of influenza. For the development of a universal influenza vaccine, we have to “do better than Nature”, since even na ...
Voir le projet
8
Participants partenaires
TERMINÉ
Oral Vaccination against Clostridium difficile Infection (CDVAX)
Date du début: 1 juin 2013, Date de fin: 30 nov. 2016,
Clostridium difficile infection (CDI) is a major threat to public health in the industrialised world, particularly in Europe. In many EU countries C. difficile now eclipses Methicillin resistant S. aureus (MRSA) with hospital acquired infection mortality exceeding that of MRSA by a factor of four. C. difficile is resistant to a wide range of antibiotics with hypervirulent and multiple drug resista ...
Voir le projet
5
Participants partenaires
TERMINÉ
Clinical development of TA-101 for the treatment of rheumatoid arthritis (TA101-GOCLIN)
Date du début: 1 oct. 2013, Date de fin: 30 nov. 2015,
...gh the skin without the pain of conventional injections.To achieve the above mentioned objectives, TA101GOCLIN gathered three competitive SMEs from Portugal, Belgium and The Netherlands. TechnoPhage, Q-Biologicals and MyLife Technologies, respectively, will be responsible for developing the clinical data of Phase I for TA101, develop an upscale method for production of the drug, and develop the mi ...
Voir le projet